Loading…
LeonaBio, Inc. is projected to rise to $8.74 by 2027, a +24% move from its current price of $7.06. LONA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $6.79 | $7.06 | $7.35 | +0.07% |
| Aug 6 | $6.68 | $7.07 | $7.48 | +0.14% |
| Aug 7 | $6.61 | $7.07 | $7.58 | +0.21% |
| Aug 8 | $6.54 | $7.08 | $7.66 | +0.28% |
| Aug 9 | $6.48 | $7.08 | $7.74 | +0.35% |
| Aug 10 | $6.43 | $7.09 | $7.81 | +0.41% |
| Aug 11 | $6.39 | $7.09 | $7.88 | +0.48% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.39 | $7.09 | $7.88 | +0.48% |
| Week 2 | $6.15 | $7.13 | $8.27 | +0.97% |
| Week 3 | $5.97 | $7.16 | $8.59 | +1.46% |
| Week 4 | $5.84 | $7.20 | $8.88 | +1.95% |
| Week 5 | $5.72 | $7.23 | $9.14 | +2.44% |
| Week 6 | $5.62 | $7.27 | $9.40 | +2.94% |
| Week 7 | $5.53 | $7.30 | $9.64 | +3.44% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
LeonaBio, Inc. is a clinical-stage biopharmaceutical company that develops novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. Its lead products include lasofoxifene and ATH-1105, a novel small molecule therapy in development.
Its pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of diabetic neuropathy, which is in phase 1 clinical trial; and ATH-1017 for the treatment of Alzheimer's disease and Parkinson's disease, which is in phase 2 clinical trial, as well as early compounds which are in preclinical phase.
The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
LeonaBio, Inc. (LONA) is a healthcare company with a current price of $7.24 and a market cap of $68.01M. It is currently ranked 4325 by market capitalization.
The forecast outlook shows a bullish trajectory over time, with the 2026 average price at $7.24 and rising in later years. The 2027 average is $9.42 (ROI 30.1), the 2028 average is $9.61 (ROI 32.7), and the 2029 average is $10.22 (ROI 41.2).
Further out, the forecast lists the 2030 average at $9.83 (ROI 35.8), 2031 at $9.47 (ROI 30.9), and 2032 at $11.43 (ROI 57.9). Longer-horizon targets show a continued uptrend with 2033 at $14.14 (ROI 95.3), 2034 at $16.23 (ROI 124.1), and 2035 at $16.63 (ROI 129.7). The far-out projections include 2040 at $24.48 (ROI 238.2) and 2050 at $39.87 (ROI 450.7).
These figures reflect a bullish long-term outlook, but are estimates and not guaranteed.
A major floor 27.2% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.3% away) — a key level to hold.
The nearest ceiling, 38.2% above — a clean break opens room to run.
A major ceiling 65.4% above — clearing it would confirm fresh momentum.
Key LONA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LONA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $7.14 | Sell | $7.18 | Sell |
| MA 10 | $7.35 | Sell | $7.41 | Sell |
| MA 20 | $8.07 | Sell | $7.81 | Sell |
| MA 50 | $8.55 | Sell | $8.32 | Sell |
| MA 100 | $8.99 | Sell | $8.21 | Sell |
| MA 200 | $7.05 | Buy | $7.54 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.59 | Neutral |
| Stoch RSI (14) | 17.35 | Buy |
| CCI (20) | -80.67 | Neutral |
| Williams %R (14) | -96.47 | Info |
| MACD (12,26,9) | -0.09 | Sell |
| ROC (12) | -17.23 | Sell |
| Bollinger %B (20,2) | 0.23 | Neutral |
| Stochastic %K (14) | 3.53 | Buy |
| TRIX (15) | -0.61 | Sell |
| Awesome (5,34) | -1.12 | Sell |
| Ultimate (7,14,28) | 31.73 | Neutral |
| Momentum (10) | -0.16 | Sell |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 7.02 | Buy |
| ADX (14) | 18.07 | Neutral |
| ATR (14) | 0.32 | Info |
The 30-day technical picture is NEUTRAL with RSI(14) at 40. The 50-day simple moving average (SMA) is $8.95 and the 200-day SMA is $6.95, signaling a mixed near-term trend.
Near-term support is at $7.22 and resistance at $9.76, suggesting a shallow range around the current price. The 30-day range spans from $5.40 to $9.71, indicating room for movement within a modestly wide band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.34 | $7.06 | $9.13 | 0% | Neutral | |
| $6.69 | $8.74 | $12.24 | +24% | Bullish | |
| $6.72 | $9.17 | $13.52 | +30% | Bullish | |
| $6.73 | $9.52 | $14.60 | +35% | Bullish | |
| $6.18 | $9.03 | $14.31 | +28% | Bullish | |
| $5.91 | $8.89 | $14.49 | +26% | Bullish | |
| $6.38 | $9.87 | $16.50 | +40% | Bullish | |
| $7.39 | $11.75 | $20.09 | +66% | Bullish | |
| $8.58 | $13.99 | $24.42 | +98% | Bullish | |
| $8.39 | $14.02 | $24.94 | +99% | Bullish | |
| $10.39 | $19.44 | $37.45 | +175% | Bullish | |
| $14.44 | $32.08 | $69.22 | +354% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $4.34 | $7.06 | $8.51 | +0.00% |
| September 2026 | $5.98 | $7.17 | $8.90 | +1.54% |
| October 2026 | $6.21 | $7.52 | $9.47 | +4.87% |
| November 2026 | $6.04 | $7.37 | $9.40 | -1.95% |
| December 2026 | $5.75 | $7.08 | $9.13 | -4.02% |
Click any year to see its month-by-month LONA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, LONA is projected to trade between $4.34 and $9.13, averaging $7.06 — a potential gain of 0% from today's $7.06. A consolidation phase looks the most probable path here.
LeonaBio, Inc.'s 2027 outlook centres on $8.74, within a $6.69 to $12.24 range. That is up +24% on the projected 2026 average. That marks a +24% change versus current levels. Momentum favours further upside here.
By 2028, LONA could reach as high as $13.52, with a base case around $9.17 and support toward $6.72 — roughly +30% from $7.06. Buyers look set to stay in control over this stretch.
Expect LONA to range from $6.73 to $14.60 through 2029. The $9.52 average target implies a +35% move from current prices. That is up +4% on the projected 2028 average. Momentum favours further upside here.
The LONA price prediction for 2030 points to an average of $9.03 (low $6.18, high $14.31) — a potential gain of +28% on today's $7.06. Buyers look set to stay in control over this stretch.
In 2031, LONA is projected to trade between $5.91 and $14.49, averaging $8.89 — a potential gain of +26% from today's $7.06. That is -2% versus the projected 2030 average. Momentum favours further upside here.
LeonaBio, Inc.'s 2032 outlook centres on $9.87, within a $6.38 to $16.50 range. That is up +11% on the projected 2031 average. That marks a +40% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, LONA could reach as high as $20.09, with a base case around $11.75 and support toward $7.39 — roughly +66% from $7.06. Momentum favours further upside here.
Expect LONA to range from $8.58 to $24.42 through 2034. The $13.99 average target implies a +98% move from current prices. That is up +19% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The LONA price prediction for 2035 points to an average of $14.02 (low $8.39, high $24.94) — a potential gain of +99% on today's $7.06. Momentum favours further upside here.
In 2040, LONA is projected to trade between $10.39 and $37.45, averaging $19.44 — a potential gain of +175% from today's $7.06. That is up +39% on the projected 2035 average. Buyers look set to stay in control over this stretch.
LeonaBio, Inc.'s 2050 outlook centres on $32.08, within a $14.44 to $69.22 range. That is up +65% on the projected 2040 average. That marks a +354% change versus current levels. Momentum favours further upside here.
Investing $1,000 in LONA today (≈ 141.643059 LONA) could be worth
$4,543.72
+$3,543.72 (+354%) by 2050 · US Dollar
Based on the average projected LONA price of $32.08 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LONAwould be worth at today's price.
$1,000 invested in LONA on Jul 31, 2025 (≈ 263.157898 LONA) would be worth
$1,857.89
+$857.89 (+85.8%) today · 1.86× · US Dollar
Based on a LONA entry price of $3.8 vs. today's $7.06.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.39 | $955.35 | -4.5% |
| 1 month ago | $8.38 | $842.48 | -15.8% |
| 3 months ago | $8.82 | $800.45 | -20.0% |
| 6 months ago | $4.65 | $1,518.28 | +51.8% |
| 1 year ago | $3.8 | $1,857.89 | +85.8% |
| All time (5.0y) ago | $104.1 | $67.82 | -93.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LONA forecast.
Our base-case forecast reaches $14.00 around 2035.
Implied market cap at $14.00: $131.51M
The multi-year forecast shows a bullish trajectory across many years, with the average price rising from $7.24 in 2026 to higher levels in later years (e.g., $9.42 in 2027, $9.83 in 2030, $24.48 in 2040, and $39.87 in 2050).
ROI figures accompany several years, including 30.1% in 2027, 32.7% in 2028, 41.2% in 2029, 35.8% in 2030, 30.9% in 2031, 57.9% in 2032, 95.3% in 2033, 124.1% in 2034, 129.7% in 2035, 238.2% in 2040, and 450.7% in 2050.
These are estimates, not guarantees, and future results depend on factors not shown here. The long horizon suggests substantial upside potential, but investors should consider the inherent uncertainty in clinical-stage biopharma valuations.
Tap a question to reveal the answer.
The forecasted average price for 2030 is $9.83 with a minimum of $6.50 and a maximum of $16.10, and an estimated ROI of 35.8, with sentiment labeled BULLISH.
The provided forecast shows bullish sentiment from 2027 onward, with rising averages (e.g., $9.42 in 2027 and $9.83 in 2030) and positive ROI figures (e.g., 30.1% in 2027, 32.7% in 2028, 41.2% in 2029, 35.8% in 2030). The 2026 figure is neutral. These are estimates, not guarantees.
Yes. The forecast shows years with maximum values above $15, including a max of $16.15 in 2029 and higher in 2032 ($19.84) and beyond, while the 2030 max is $16.10.
LONA.
The 30-day range is from $5.40 to $9.71, with near-term support at $7.22 and resistance at $9.76.
LeonaBio, Inc. Community Discussion
0Share your LeonaBio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.